Cancer Stem Cells as a new promising approach of efficient oncological treatment - the review of literature

Klaudia Daria Szumna, Faustyna Piędel, Patryk Jasielski, Sylwia Grosman, Kamila Habaj, Agata Filip



Introduction and purpose:

For many years a lot of research projects have been conducted with the aim to discover special cells, which are responsible for a neoplasm development. One of the theories concerns cancer stem cells (CSCs). This theory presumes the existence of original, undifferentiated cancer cells. These cells are capable of transform to all types of cells in neoplasm mass. The purpose of this study was to review the currently available data about the theory of CSCs and especially potential usage of this theory in oncological treatment. Pubmed and Scopus databases from the last 10 years were searched for phrase “cancer stem cells”. 

 A brief description of the state of knowledge:


Impaired signalling pathways lead to an occurrence of CSCs which may contribute to the development of neoplasm eventually. It is proved, that gamma secretase inhibitors impede Notch signalling pathway, which leads to a decrease of tumour markers expression and consequently decline in vivo tumour growth. It is believed that epigenetic mechanisms, including DNA methylation, histones alteration and RNA orientation are pivotal regulators of CSCs. It was shown, that histone deacetylases (HDAC) modulate refractoriness on chemotherapy in haematological tumours. It is also evidenced that peculiar designed microRNA directly inhibit CD44 which suppresses prostatic cancer stem cells and its metastases. CSCs have high expression of programmed death-ligand 1 (PD-L1) including breast and colon cancer, which proclaims in favour of immunotherapy aimed on CSCs. 


Constantly growing knowledge about CSCs biology is creating new opportunities of detection, isolation and design of the therapies aimed on CSCs. 


Cancer stem cells; elective treatment; chemotherapy; remission

Full Text:



IARC. Global Cancer Observatory (GLOBOCAN) Cancer Tomorrow 2018 Estimates. Available at:

Badowska-Kozakiewicz AM, Budzik MP. Cancer stem cells – a new chance for successful treatment of cancer. Studia Medyczne 2015; 31 (2): 139–145.

Wieczorek K, Niewiarowska J. Cancer stem cells. Postepy Hig Med Dosw. 2012; 66: 629-636.

Nassar D, Blanpain C. Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annu Rev Pathol. 2016; 11: 47-76.

Turdo A, Veschi V, Gaggianesi M, Chinnici A, Bianca P, Todaro M et al.Meeting the Challenge of Targeting Cancer Stem Cells. Front Cell Dev Biol. 2019; 7: 16.

Szaryńska M, Olejniczak A, Kmieć Z. The role of cancer stem cells in pathogenesis of colorectal cancer. Postepy Hig Med Dosw. 2016; 70: 1469-1482.

Toh TB, Lim JJ, Chow EK. Epigenetics in cancer stem cells. Mol Cancer. 2017; 16(1): 29.

Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell. 2010; 17(5): 427-42.

Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012; 21(2): 266-81.

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2): 211-5.

Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014; 28(12): 1101-7, 1110.

Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J et al. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016; 130(3): 571-579.

Wu Y, Chen M, Wu P, Chen C, Xu ZP, Gu W. Increased PD-L1 expression in breast and colon cancer stem cells. Clin Exp Pharmacol Physiol. 2017; 44(5): 602-604.

Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015; 16: 1.

Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M et al. Tenascin-C Protects Cancer Stem–like Cells from Immune Surveillance by Arresting T-cell Activation. Cancer Res. 2015; 75(10): 2095-108.

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:


PBN Poland



Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2019 = 100.00 ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18

RG Journal impact over time

RG Journal impact

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski


Partnerzy platformy czasopism